Inhibrx Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| INBX | 688382.SS | IVA | SNDX | OBX | BHVN | |
|---|---|---|---|---|---|---|
| Market cap | 1.28B | 8.38B | 914.17M | 940.80M | 678.88M | 2.30B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -9.9 | -43.8 | -5.2 | -14.4 | -5.2 | -8.2 |
| Price/book | -24.1 | 6.6 | 13.8 | -54.7 | -0.8 | -23.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +7.12% | −48.70% | −7.42% | −28.86% | −37.20% | +78.66% |
| Today | +7.01% | +4.33% | −3.97% | −26.87% | −16.93% | −2.37% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All INBX news ›Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Cytokinetics (NASDAQ:CYTK)
Posted by Mitch Edgeman on Oct 25th, 2026 Cytokinetics (NASDAQ:CYTK – Get Free Report) and Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
Inhibikase Appoints Scott Wasserman to Board of Directors
Inhibikase Therapeutics ( (IKT) ) has issued an update. The most recent analyst rating on (IKT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock…
Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) CEO Acquires $848,982.40 in Stock
Posted by Kim Johansen on Oct 17th, 2026 Mark Lappe also recently made the following trade(s): NASDAQ:INBX opened at $89.83 on Friday. Inhibrx Biosciences, Inc. has a 52-week low of $28.16 and a 52-week high of $155.29. The stock has a…
Inhibrx Biosciences CEO trusts buy 10,040 shares
Two CEO-linked trusts buy 10,040 Inhibrx Biosciences (INBX) shares; no trading plan is reported. Stock Titan - [Form 4] Inhibrx Biosciences, Inc. Insider Trading Activity Inhibrx Biosciences CEO trusts buy 10,040 shares The chief executive…
InMed Pharmaceuticals: ADAR1 funds buy 9,569 shares
At $1.32–$1.33 a share, ADAR1 funds buy 9,569 shares of InMed Pharmaceuticals (INM). Stock Titan - [Form 4] InMed Pharmaceuticals Inc. Insider Trading Activity InMed Pharmaceuticals: ADAR1 funds buy 9,569 shares The shares were held by…
Inhibrx Announces Participation in Upcoming Scientific Conferences
Oct 13, 2026, 16:00 ET SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic…
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Stock Has Consensus Price Target of $197.50
Posted by Danessa Lincoln on Oct 6th, 2026 Read Our Latest Analysis on INBX Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com3
- stocktitan.net2
- theglobeandmail.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.